Engineering Technologies and Clinical Translation
Volume 3 of Delivery Strategies and Engineering Technologies in Cancer Immunotherapy
- 524 pages
- English
- ePUB (mobile friendly)
- Only available on web
Engineering Technologies and Clinical Translation
Volume 3 of Delivery Strategies and Engineering Technologies in Cancer Immunotherapy
About This Book
Engineering Technologies and Clinical Translation: Volume 3: Delivery Strategies and Engineering Technologies in Cancer Immunotherapy examines the challenges of delivering immuno-oncology therapies, focusing specifically on the development of solutions for drug delivery and its clinical outcomes. Immuno-oncology (IO) is a growing field of medicine at the interface of immunology and cancer biology leading to development of novel therapeutic approaches, such as chimeric antigen receptor T-cell (CAR-T) and immune checkpoint blockade antibodies, that are clinically approved approaches for cancer therapy. Although currently approved IO approaches have shown tremendous promise for select types of cancers, broad application of IO strategies could even further improve the clinical success, especially for diseases such as pancreatic cancer, brain tumors where the success of IO so far has been limited. This volume of Delivery Strategies and Engineering Technologies in Cancer Immunotherapy discusses biomaterial, microfluidic, and biodegradable devices, engineered microbes, personalized medicine, clinical approval process, and many other IO technologies.
Engineering Technologies and Clinical Translation: Volume 3: Delivery Strategies and Engineering Technologies in Cancer Immunotherapy creates a comprehensive treaty that engages the scientific and medical community who are involved in the challenges of immunology, cancer biology, and therapeutics with possible solutions from the nanotechnology and drug delivery side.
- Explores engineering technologies and their clinical translation in a comprehensive way
- Presents forecasting on the future of nanotechnology and drug delivery for IO
- Engages the scientific and medical community who are involved in the challenges of immunology, cancer biology, and therapeutics with possible solutions from the nanotechnology and drug delivery side
Frequently asked questions
Information
Table of contents
- Cover image
- Title page
- Table of Contents
- Copyright
- Dedication
- Contributors
- Preface
- Acknowledgments
- Chapter One: Engineering solutions to design CAR-T cells
- Chapter Two: Engineered microbes for cancer immunotherapy
- Chapter Three: Polymeric scaffolds for antitumor immune cell priming
- Chapter Four: Biomaterials and devices for immunotherapy
- Chapter Five: Engineered devices for tumor microenvironment immune modulation
- Chapter Six: Tumor-on-a-chip devices for cancer immunotherapy
- Chapter Seven: Challenges and opportunities of nanotechnology in cancer immunotherapy
- Chapter Eight: Stromal modulation strategies to improve immunotherapy response in cancer
- Chapter Nine: Spatial mapping of the tumor immune microenvironment
- Chapter Ten: Nucleic acid biomarker technology for cancer immunotherapy
- Chapter Eleven: Proteomic biomarker technology for cancer immunotherapy
- Chapter Twelve: Personalized cancer immunotherapy
- Chapter Thirteen: Image-guided cancer immunotherapy
- Chapter Fourteen: Clinical translation and challenges in cancer immunotherapies
- Index